Month: February 2022

         February 16, 2021 – Hamilton, Bermuda Fourth Quarter 2021 Result Presentation Please find enclosed the presentation of Flex LNG Ltd.’s fourth quarter 2021 results which will be presented in a webcast and conference call at 15:00 CET (9:00 a.m. EST) today, Wednesday February 16, 2022. The presentation is also available on our website https://www.flexlng.com/category/presentations/   Attend by Webcast:Use to the follow link prior to the webcast: https://edge.media-server.com/mmc/p/42dfa2a2 Attend by Conference Call: Applicable dial-in telephone numbers are as follows: Norway: +47 21 56 30 15United Kingdom: +44 (0) 2071 928 338United Kingdom, local: 08444 819 752United States: +1 646 741 3167United States (toll free): +1 877 870 9135 Confirmation Code:   3025688 The presentation material which will be used in the teleconference/webcast...

Amsterdam, 16 February 2022 – Heineken Holding N.V. (EURONEXT: HEIO; OTCQX: HKHHY) announces:    Key Highlights         The net result of Heineken Holding N.V.’s participating interest in Heineken N.V. for 2021 amounts to €1.663 million Net revenue (beia) organic growth 12.2%; per hectolitre 8.3% Consolidated beer volume 4.6% organic growth Heineken® volume growth 17.4%, well ahead of 2019 Gross savings close to €1.3 billion, on-track to deliver €2 billion by 2023 Operating profit (beia) organic growth 43.8%, margin 15.6% (+331 bps) Net profit (beia) €2,041 million, 80.2% organic growth Diluted EPS (beia) €3.54 (2020: €2.00)    Financial Summary1         IFRS Measures € million Total growth   BEIA Measures € million Organic growth2Revenue         26,583...

February 16, 2022 – Hamilton, BermudaFlex LNG Ltd. (“Flex LNG” or the “Company”) today announced its unaudited financial results for the fourth quarter and year ended December 31, 2021. Highlights:All time high revenues of $114.6 million for the fourth quarter 2021, compared to $81.8 million for the third quarter 2021. All time high net income of $69.4 million and basic earnings per share of $1.31 for the fourth quarter 2021, compared to net income of $32.8 million and basic earnings per share of $0.62 for the third quarter 2021. Average Time Charter Equivalent1 (“TCE”) rate of $95,908 per day for the fourth quarter 2021, compared to $68,341 per day for the third quarter 2021. All time high adjusted EBITDA1 of $95.5 million for the fourth quarter 2021, compared to $64.5 million for the third quarter 2021. All...

VANCOUVER, British Columbia, Feb. 16, 2022 (GLOBE NEWSWIRE) — COVER TECHNOLOGIES INC. (CSE: COVE) (OTC: MGPRF) (Frankfurt: 304A) (the “Company” or “Cover”) is pleased to announce that it has closed a non-brokered private placement and issued 1,453,431 common shares (“Shares”) at a price of CAD $0.255 per Share for gross aggregate proceeds of $370,624.91 (the “Private Placement”). No finder’s fees were paid on the Private Placement. The Company intends to use the net proceeds from the Private Placement for payment of current payables and general working capital purposes. All securities issued in connection with the Private Placement are subject to a statutory hold period of four months and one day from the date of issuance. On behalf of the Board of Directors of the Company, COVER TECHNOLOGIES INC. “Dorian Banks” Dorian...

NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced the outcome of the U.S. Food and Drug Administration (“FDA”) joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee on IV tramadol. In the final part of the public meeting, the Advisory Committee voted yes or no on the following question: “Has the Applicant submitted adequate information to support the position that the benefits of their product outweigh the risks for the management of acute pain severe enough to require an opioid analgesic in an inpatient setting?” The results are 8 yes votes and 14 no votes. FDA Advisory Committees provide the FDA...

Progress in the zoning process on several strategic projects, together with improved market conditions, contributed to $580.7 million in incremental property values, which in turn led to net income and comprehensive income for Q4 2021 increasing by $603.7 million as compared to the same period in 2020, representing an increase of $3.46 per Unit; FFO per Unit for Q4 2021 increased by $0.06 or 12.0% as compared to the same period in 2020; Continued advancement of non-retail pipeline of 283 projects representing approximately 59 million square feet across the network (41 million square feet at the Trust’s share); and Portfolio continues to provide recurring income with an in-place occupancy rate of 97.4% and committed occupancy rate of 97.6%.TORONTO, Feb. 15, 2022 (GLOBE NEWSWIRE) — SmartCentres Real Estate Investment Trust (“SmartCentres”,...

MALVERN, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that the Company’s Board of Directors has approved a 1-for-35 reverse stock split of its common shares (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. Eastern time on February 16, 2022 and the Company’s common stock will open for trading on The Nasdaq Capital Market on a post-split basis under the Company’s existing trading symbol “BXRX”. At such time, the Company’s common stock will also commence trading under a new CUPSIP number, 07160F206. Baudax Bio expects that the Reverse Stock Split, which was approved by shareholders at a special shareholder meeting on February 9, 2022 will increase...